ReviewPLoS pathogens2010
Enhancing oral vaccine potency by targeting intestinal M cells.
Review in PLoS pathogens, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Preclinical Evaluation of Bacterial Lysates in Murine Disease Models: A Systematic Review.Immunity, inflammation and disease · 2026Pooled it
- Pooled it
- Review
- Sequential Barrier Navigation by Yeast β-Glucan-Engineered Liposomal Nanovaccines Potentiates Oral Melanoma Immunotherapy.International journal of nanomedicine · 2026Article
- Glycosylated SARs Cov 2 interaction with plant lectins.Glycoconjugate journal · 2024Review
- Mannose-specific plant and microbial lectins as antiviral agents: A review.Glycoconjugate journal · 2024Review
- Synergistic Effect of Retinoic Acid and Lactoferrin in the Maintenance of Gut Homeostasis.Biomolecules · 2024Review
- Expression ofVaccines · 2023Article
- Application of Nano-Delivery Systems in Lymph Nodes for Tumor Immunotherapy.Nano-micro letters · 2023Review
- Commensal gut microbiota-based strategies for oral delivery of therapeutic proteins.Trends in pharmacological sciences · 2022Review
- Mucosal delivery of nanovaccine strategy against COVID-19 and its variants.Acta pharmaceutica Sinica. B · 2022Review
- Trafficking and retention of protein antigens across systems and immune cell types.Cellular and molecular life sciences : CMLS · 2022Review
- Oral drug delivery for immunoengineering.Bioengineering & translational medicine · 2022Review
- Mucosal Immunization with DTaP Confers Protection againstInfection and immunity · 2021Article
- Platforms for Production of Protein-Based Vaccines: From Classical to Next-Generation Strategies.Biomolecules · 2021Review
- Colonisation Factor CD0873, an Attractive Oral Vaccine Candidate againstMicroorganisms · 2021Article
- Protective Passive Immunity inVaccines · 2020Article
- Recent Advances in Encapsulation, Protection, and Oral Delivery of Bioactive Proteins and Peptides using Colloidal Systems.Molecules (Basel, Switzerland) · 2020Review
- Preliminary Volumetric Calculation of the Mucosal Surface in the Nares of Lambs Using a Segmentation of Computed Tomographic Images.Frontiers in veterinary science · 2020Article
- Oral Deliverable Mucoadhesive Chitosan-International journal of nanomedicine · 2020Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The immune system in the gastrointestinal tract plays a crucial role in the control of infection, as it constitutes the first line of defense against mucosal pathogens. The attractive features of oral immunization have led to the exploration of a variety of oral delivery systems. However, none of these oral delivery systems have been applied to existing commercial vaccines. To overcome this, a new generation of oral vaccine delivery systems that target antigens to gut-associated lymphoid tissue is required. One promising approach is to exploit the potential of microfold (M) cells by mimicking the entry of pathogens into these cells. Targeting specific receptors on the apical surface of M cells might enhance the entry of antigens, initiating the immune response and consequently leading to protection against mucosal pathogens. In this article, we briefly review the challenges associated with current oral vaccine delivery systems and discuss strategies that might potentially target mouse and human intestinal M cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.